Research Sample bioBank
Can’t find what you’re looking for? Contact us.
Or, need help ordering? 805.528.4341
Get Weekly Research Sample Updates in your Inbox:
Hepatitis B (HBV) Genotype D Clinical Research Samples
Discovery Life Sciences provides the highest quality Hepatitis B (HBV) Genotype D Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Hepatitis B (HBV) Genotype D Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
Advanced Data View:
Showing 58 of 58 total samples
Buy | Product ID | Sample | Origin | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test Data 1 | Sample Detail 1 | Test 2 | Test Data 2 | Sample Detail 2 | Test 3 | Test Data 3 | Sample Detail 3 | Product Details | Price | Buy | Additional Information 1 | Additional Data 1 | Additional Information 2 | Additional Data 2 | Additional Information 3 | Additional Data 3 | Additional Information 4 | Additional Data 4 | Additional Information 5 | Additional Data 5 | Additional Detail 5 | Additional Information 6 | Additional Data 6 | Additional Detail 6 | Additional Information 7 | Additional Data 7 | Additional Detail 7 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DLS12-0435 | Hepatitis B (HBV) Genotype D | Italy | Plasma | 0.75 | 1.00 | $95.00 | 50 Y | M | U/A | <-70°C | 11-Apr-13 | Abbott Realtime PCR | 697 IU/mL | Siemens TruGene HBV | D | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Household contact | Symptoms | Fatigue; Itching; Nausea | Additional Testing | ALT: 890; AST: 1534; ALP: 226; LDH: 1529; Bilirubin: 26.79; Serum Creatinine: 3.64 mg/dL; Hepatocellular carcinoma | Hepatitis Serology | HBsAg+; HBeAg-; Anti HBeAg+ (Abbott) | |||||||||||||
| DLS12-7507 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 41 Y | F | U/A | <-70°C | 28-Nov-06 | Roche cobas | 2,082 IU/mL | HBV Ct Value - 29 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co+ (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott IMX) | ||||||||||||
| DLS12-7508 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 2.00 | $40.00 | 43 Y | M | U/A | <-70°C | 23-Aug-07 | Roche cobas | 83 IU/mL | HBV Ct Value - 31 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co+ (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott IMX) | ||||||||||||
| DLS12-7514 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 55 Y | F | U/A | <-70°C | 10-Dec-07 | Roche cobas | 44 IU/mL | HBV Ct Value - 32 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (324) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott IMX) | ||||||||||||
| DLS12-7516 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 2.00 | $40.00 | 23 Y | F | U/A | <-70°C | 11-Feb-08 | Roche cobas | 750 IU/mL | HBV Ct Value - 33 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (475) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect) | ||||||||||||
| DLS12-7518 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.25 | 2.00 | $40.00 | 18 Y | M | U/A | <-70°C | 27-May-10 | Roche cobas | 662 IU/mL | HBV Ct Value - 28 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (613) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect) Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS12-7521 | Hepatitis B (HBV) Genotype D | Russia | Citrated Plasma | 0.50 | 1.00 | $40.00 | 50 Y | M | U/A | <-70°C | 12-Feb-11 | Roche cobas | 52 IU/mL | HBV Ct Value - 33 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (182) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect) Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS12-7522 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 34 Y | M | U/A | <-70°C | 29-Dec-11 | Roche cobas | 534 IU/mL | HBV Ct Value - 30 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (383) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect) Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS12-7525 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.50 | 1.00 | $40.00 | 26 Y | F | U/A | <-70°C | 14-Feb-12 | Roche cobas | 21 IU/mL | HBV Ct Value - 35 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (282) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect) Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS12-7526 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 45 Y | M | U/A | <-70°C | 03-Mar-12 | Roche cobas | <20 IU/mL | HBV Ct Value - 35 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (274) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect) Anti-HBcAg IgM- (Abbott Architect) | |||||||||||||
| DLS12-7531 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 47 Y | M | U/A | <-70°C | 07-May-12 | Roche cobas | <20 IU/mL | HBV Ct Value - 33 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (248) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect) Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS12-8107 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 0.75 | 1.00 | $40.00 | 30 Y | M | U/A | <-70°C | 29-Sep-12 | Roche cobas | 499 IU/mL | HBV Ct Value - 31 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (495) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect) Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS12-8108 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.25 | 1.00 | $40.00 | 29 Y | M | U/A | <-70°C | 05-Oct-12 | Roche cobas | 502 IU/mL | HBV Ct Value - 29 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (570) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect) Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS12-8111 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 0.25 | 1.00 | $40.00 | 50 Y | M | U/A | <-70°C | 10-Oct-12 | Roche cobas | Not Detected | HBV Ct Value - 34 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | N/A | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (542) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect) Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS12-8482 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 36 Y | M | U/A | <-70°C | 03-Nov-12 | Viral Load | Not Available | Innogenetics INNO-LIPA | D | $40.00 | 3-series HepB Vaccine | Unknown | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co 719.39 (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | |||||||||||||
| DLS13-03343 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.50 | 1.00 | $40.00 | 33 Y | M | U/A | < -70C | 16-Feb-08 | Roche cobas | 495 IU/mL | HBV Ct Value - 28 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (483) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03345 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.50 | 1.00 | $40.00 | 27 Y | M | U/A | < -70C | 21-Dec-06 | Roche cobas | 588 IU/mL | HBV Ct Value - 30 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (417) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03354 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 0.50 | 1.00 | $40.00 | 63 Y | F | U/A | < -70C | 17-Jan-11 | Roche cobas | 164 IU/mL | HBV Ct Value - 27 | Innogenetics INNO-LIPA | D | $40.00 | 3- Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (355) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03357 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 28 Y | M | U/A | < -70C | 03-Dec-10 | Roche cobas | 430 IU/mL | HBV Ct Value - 29 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infections Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (466) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03366 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 27 Y | M | U/A | < -70C | 10-Nov-12 | Roche cobas | 32 IU/mL | HBV Ct Value - 29 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (531.27) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03369 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 0.75 | 1.00 | $40.00 | 33 Y | M | U/A | < -70C | 09-Feb-12 | Roche cobas | 314 IU/mL | HBV Ct Value - 29 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (524) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03372 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 56 Y | F | U/A | < -70C | 11-Apr-11 | Roche cobas | 76 IU/mL | HBV Ct Value - 28 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (253) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03373 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 42 Y | M | U/A | < -70C | 11-Jan-12 | Roche cobas | 42 IU/mL | HBV Ct Value - 31 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infections Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (252) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03387 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.50 | 1.00 | $40.00 | 47 Y | M | U/A | < -70C | 25-Jun-11 | Roche cobas | 381 IU/mL | HBV Ct Value - 27 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (312) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03388 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 0.75 | 1.00 | $40.00 | 44 Y | F | U/A | < -70C | 11-Jan-13 | Roche cobas | 156 IU/mL | HBV Ct Value - 30 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (485) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03415 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 50 Y | F | U/A | < -70C | 14-Feb-07 | Roche cobas | 61 IU/mL | HBV Ct Value - 29 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (272) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-03417 | Hepatitis B (HBV) Genotype D | Spain | Citrated Plasma | 1.00 | 1.00 | $40.00 | 53 Y | M | U/A | < -70C | 20-Nov-06 | Roche cobas | 971 IU/mL | HBV Ct Value - 26 | Innogenetics INNO-LIPA | D | $40.00 | 3-Series HepB Vaccine | N/A | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | N/A | Symptoms | Asymptomatic | Additional Testing | N/A | Hepatitis Serology | HBsAG S/Co (224) (Abbott PRISM); Anti-HBcAg (IgG+IgM)+ (Abbott Architect); Anti-HBcAg IgM- (Abbott Architect) | ||||||||||||
| DLS13-11741 | Hepatitis B (HBV) Genotype D | Germany | Plasma | 1.00 | 1.00 | $95.00 | 35 Y | M | U/A | < -70C | 01-Apr-14 | Abbott RealTime PCR | 3,780 IU/mL | Sequencing In-house Assay | D | $95.00 | 3-series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Neo-natal transmission | Symptoms | None | Hepatitis Serology | HBsAg+ (CMIA) | Abbott RealTime PCR | Positive | 13-Mar-2018 | ||||||||||||
| DLS13-11829 | Hepatitis B (HBV) Genotype D | Italy | Plasma | 1.00 | 3.00 | $95.00 | 60 Y | F | White | < -70C | 06-Nov-13 | Roche cobas | 80 IU/mL | Siemens TruGene HBV | D | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | No symptoms | Additional Testing | ALT: 16; AST: 17; LDH: 418; Bilirubin: 1.1; Serum Creatinine: 0.5 mg/dL; Grade 1 Stage 2; Chronic Hepatitis | Hepatitis Serology | HBsAg-; HBeAg-; HBeAb+; HBcAb+ (CMIA) | |||||||||||||
| DLS13-12210 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 0.50 | 1.00 | $40.00 | U/A | U/A | < -70C | 23-Jun-08 | Roche cobas | 19 cps/mL | Gene S Sequencing In-house Assay | D | Mutations: G130R S132Y | Immuno-Enzymatique | ayw2 | Serotype | $40.00 | Elisa | 50.800 | Prism | 391.490 | Confirmation | Pos | Ag Hbe Negative | Ac Hbe Positive | HBc Positive | |||||||||||||
| DLS13-12211 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 1.00 | 2.00 | $40.00 | U/A | U/A | < -70C | 20-Aug-08 | Roche cobas | 7 copies/mL | Gene S Sequencing In-house Assay | D | Immuno-Enzymatique | trop faible | Serotype | $40.00 | Elisa | 37.852 | Elisa 2 | 9.973 | Confirmation | Pos | 4eme, 5eme valeur Elisa: 14,095; 13,952 | 6eme, 7eme valeur Elisa: 0,333; 0,349 | Hepatitis Serology | HBc Positive | |||||||||||||
| DLS13-12228 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 1.00 | 2.00 | $40.00 | U/A | U/A | < -70C | 10-Jul-08 | Roche cobas | <6 cps/mL | Gene S Sequencing In-house Assay | D3 | Immuno-Enzymatique | ayw3 | Serotype | $40.00 | Elisa | 54.545 | Prism | 382.210 | Confirmation | Pos | HBc Positive | Hepatitis Serology | |||||||||||||||
| DLS13-12242 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 0.50 | 1.00 | $40.00 | U/A | U/A | < -70C | 25-May-09 | Roche cobas | 1,179 cps/mL | Gene S Sequencing In-house Assay | D | Immuno-Enzymatique | ayw2 | Serotype | $40.00 | Prism | 656.060 | Elisa | 43.246 | Confirmation | Pos | HBc Positive | Hepatitis Serology | HBc IgM Negative | Syphilis positive : boite 28 : J8 | |||||||||||||
| DLS13-12254 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 1.00 | 1.00 | $40.00 | U/A | U/A | < -70C | 14-Oct-10 | Roche cobas | 392 copies/mL | Gene S Sequencing In-house Assay | D2 | Immuno-Enzymatique | ayw2 | Serotype | $40.00 | Prism | 594.010 | Elisa | 50.000 | DGV | Pos | HBc Positive | Hepatitis Serology | Ac HBs Positive - Ac Hbe Positive | AgHBe Negative | |||||||||||||
| DLS13-12259 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 1.00 | 1.00 | $40.00 | U/A | U/A | < -70C | 11-Jan-11 | Roche cobas | 33 copies/mL | Gene S Sequencing In-house Assay | D1 | Immuno-Enzymatique | ayw2 | Serotype | $40.00 | Prism | 420.070 | Elisa | 56.727 | Confirmation | Pos | DGV | Pos | Syphilis Positive, Ac Hbe Positive | Hepatitis Serology | HBc Positive | Ag Hbe Negative | |||||||||||
| DLS13-12262 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 0.50 | 1.00 | $40.00 | U/A | U/A | < -70C | 05-Nov-11 | Roche cobas | 281 cps/mL | Gene S Sequencing In-house Assay | D | Immuno-Enzymatique | ayw2 | Serotype | $40.00 | Prism | 564.340 | Elisa | 52.117 | Confirmation | Pos | DGV | Pos | HBc Positive | Hepatitis Serology | Ag Hbe Negative | HBc IgM Negative | |||||||||||
| DLS14-31182 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 3.00 | $95.00 | 53 Y | F | White | <-70C | 05-Mar-16 | Roche Cobas | 2,084 IU/mL | 10-Dec-15 | Siemens TruGene HBV | D | 10-Dec-15 | Roche Cobas | Positive | 13-Mar-2018 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | N/A | Additional Testing | ALT: 21 IU/L; AST: 17 IU/L; Serum Creatinine: 0.74 mg/dL; 25-Nov-2015 ALP: 84 IU/L; Bilirubin: 0.21 mg/dL; Chronic Hepatitis B | 10-Dec-15 | Hepatitis Serology | HBsAg+; HBcAb+; HBeAg- HBeAb+; | 7-May-2015 | 11/25/2015 | Co-Infections | None | ||||
| DLS14-31183 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 3.00 | $95.00 | 64 Y | M | White | <-70°C | 08-Oct-15 | Roche cobas | 547 IU/mL | 17-Sep-15 | Siemens TruGene HBV | D | 17-Sep-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | None | Additional Testing | ALT: 134 U/L; AST: 50 U/L; LDH: 222 U/L; Chronic Active Hepatitis B | 5-Oct-15 | Hepatitis Serology | HBsAg+; HBeAb+; HCVAb- | 21-Sep-15 | Co-Infections | N/A | |||||||
| DLS14-31184 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 7.00 | $95.00 | 59 Y | M | White | <-70C | 18-Nov-15 | Roche Cobas | 17,600 IU/mL | 10-Nov-15 | Siemens TruGene HBV | D | 10-Nov-15 | Roche Cobas | Positive | 13-Mar-2018 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | N/A | Additional Testing | ALT: 21 IU/L; AST: 13 IU/L; ALP: 140 IU/L; Bilirubin: 1.1 mg/dL; Serum Creatinine: 1.0 mg/dL; 18-Nov-2015 LDH: 605 IU/L; Chronic Hepatitis | 9-Dec-15 | Hepatitis Serology | HBsAg+; HCVAb-; | HBeAb+; HBeAg- | 13-Jan-2016 | 1/27/2016 | Co-Infections | None | ||||
| DLS14-31178 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 4.00 | $95.00 | 50 Y | M | White | <-70°C | 26-Jun-15 | Roche cobas | 7,000 IU/mL | 17-Jun-15 | Siemens TruGene HBV | D | 17-Jun-15 | Roche Cobas | Positive | 13-Mar-2018 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | None | Additional Testing | ALT: 68 U/L; AST: 151 U/L; ALP: 53 U/L; LDH: 347 U/L; Bilirubin: 0.6 mg/dL; Serum Creatinine: 1.1; Chronic Hepatitis B | 18-Dec-14; 17-Jun-15 | Hepatitis Serology | HBsAg+; HBeAb+ | 18-Dec-14 | Co-Infections | N/A | ||||
| DLS14-31173 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 3.00 | $95.00 | 47 Y | M | White | <-70C | 17-May-16 | Roche Cobas | 826 IU/mL | 20-Apr-16 | Siemens TruGene HBV | D | 20-Apr-16 | Roche Cobas | Positive | 13-Mar-2018 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Alcohol and IV Drug Abuse | Symptoms | N/A | Additional Testing | ALT: 36 IU/L; AST: 21 IU/L; Bilirubin: 0.21 mg/dL; Chronic Hepatitis B | 15-Apr-16 | Hepatitis Serology | HBsAg+; HBeAb+; HBcAb+; | HCVAb-; | 20-Apr-2016 | 15-Feb-2016 | Co-Infections | None | ||||
| DLS14-31185 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 4.00 | $95.00 | 64 Y | M | White | <-70°C | 13-Oct-15 | Roche cobas | 60 IU/mL | 7-Oct-15 | Siemens TruGene HBV | D | 7-Oct-15 | Roche Cobas | Positive | 13-Mar-2018 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | None | Additional Testing | ALT: 67 U/L; AST: 41 U/L; LDH: 148 U/L; Bilirubin: 0.3 mg/dL; Serum Creatinine: 0.3; Chronic Active Hepatitis B | 7-Oct-15 | Hepatitis Serology | HBsAg+; HBeAb+; HCVAb- | 28-Sep-15 | Co-Infections | N/A | ||||
| DLS14-31187 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 8.00 | $95.00 | 68 Y | F | White | <-70C | 03-Oct-16 | Roche Cobas | Negative | 3-Oct-16 | Siemens TruGene HBV | D | 3-Oct-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | N/A | Additional Testing | ALT: 18 IU/L; AST: 10 IU/L; LDH: 175 IU/L; Bilirubin: 0.4 mg/dL; Serum Creatinine: 0.7 mg/dL; Chronic Hepatitis B | 3-Oct-16 | Hepatitis Serology | HBsAg+; HBeAb+; HBcAb+; HCVAb-; | 3-Oct-16 | Co-Infections | None | |||||||
| DLS14-31193 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 2.00 | $95.00 | 77 Y | M | White | <-70°C | 03-Feb-15 | Roche cobas | 1,220 IU/mL | 9-Feb-15 | Siemens TruGene HBV | D | 9-Feb-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | None | Additional Testing | ALT: 45 U/L; AST: 58 U/L; Bilirubin: 0.59 mg/dL; Serum Creatinine: 0.7; Chronic Active Hepatitis B | 9-Feb-15 | Hepatitis Serology | HBsAg+; HBsAb-; HBeAg- | 9-Feb-15 | Co-Infections | N/A | |||||||
| DLS14-31194 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 5.00 | $95.00 | 63 Y | M | White | <-70C | 05-Oct-16 | Roche COBAS AmpliPrep | 5,080 IU/mL | 27-Sep-16 | Siemens TruGene HBV | Genotype D | 27-Sep-16 | Roche COBAS AmpliPrep | Positive | 13-Mar-2018 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | None | Additional Testing | ALT: 53 IU/L; AST: 10 IU/L; LDH: 225 IU/L; Bilirubin: 0.3 mg/dL; Serum Creatinine: 0.7 mg/dL; Chronic Hepatitis B | 27-Sep-2016 | Hepatitis Serology | HBsAg+ HBeAg- HBC+ HCVAb- 8-Aug-2016 (CMIA) | Co-Infections | None | |||||
| DLS16-72178 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 14.00 | $95.00 | 42 Y | F | White | <-70C | 24-Oct-16 | Roche COBAS AmpliPrep | Negative | 24-Oct-16 | Siemens TruGene HBV | Genotype D | 24-Oct-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | None | Additional Testing | ALT: 14 IU/L; AST: 12 IU/L; LDH: 148 IU/L; Bilirubin: 0.6 mg/dL; Serum Creatinine: 0.6 mg/dL; Chronic Hepatitis B | 24-Oct-2016 | Hepatitis Serology | HBsAg+ HBeAb+ HBcAb+ HBeAg- 24-Oct-2016 (CMIA) | Co-Infections | None | ||||||||
| DLS16-72179 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 2.00 | $95.00 | 63 Y | M | White | <-70C | 30-Nov-16 | Roche COBAS AmpliPrep | 245,000 IU/mL | 21-Nov-16 | Siemens TruGene HBV | Genotype D | 21-Nov-16 | Roche COBAS AmpliPrep | Positive | 13-Mar-2018 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual Transmission | Symptoms | None | Additional Testing | ALT: 40 IU/L; AST: 41 IU/L; Bilirubin: 0.4 mg/dL; Serum Creatinine: 0.9 mg/dL; Liver Cirrhosis | 3-Oct-2016 | Hepatitis Serology | HBsAg+ HCVAb- HBcAb+ HBsAb- 3-Oct-2016 (CMIA) | Co-Infections | None | |||||
| DLS16-72181 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 3.00 | $95.00 | 76 Y | F | White | <-70C | 17-Oct-16 | Roche Cobas | 20 IU/mL | 17-Nov-16 | Siemens TruGene HBV | D | 20-Oct-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | N/A | Additional Testing | ALT: 26 IU/L; AST: 26 IU/L; LDH: 216 IU/L; Bilirubin: 0.6 mg/dL; Serum Creatinine: 0.8 mg/dL; Chronic Hepatitis B | 17-Oct-16 | Hepatitis Serology | HBsAg+; HBeAb+; HBcAb+; HBeAg- | 17-Oct-2016 | Co-Infections | None | |||||||
| DLS16-72182 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 9.00 | $95.00 | 59 Y | F | White | <-70C | 06-Dec-16 | Roche Cobas | 1,980 IU/mL | 10-Jan-17 | Siemens TruGene HBV | D | 10-Jan-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | N/A | Additional Testing | ALT: 14 IU/L; AST: 15 IU/L; Bilirubin: 0.3 mg/dL; Serum Creatinine: 0.8 mg/dL; Chronic Active Hepatitis B | 15-Nov-16 | Hepatitis Serology | HBsAg+; HBsAb+ HBcAb+; HCVAb-; | 15-Nov-16 | Co-Infections | None | |||||||
| DLS16-72190 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 4.00 | $95.00 | 74 Y | M | White | <-70C | 02-Feb-17 | Roche Cobas | 46.6 IU/mL | 23-Jan-17 | Siemens TruGene HBV | D | 23-Jan-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | N/A | Additional Testing | ALT: 14 IU/L; AST: 14 IU/L; Bilirubin: 0.6 mg/dL; Serum Creatinine: 1.1 mg/dL; Chronic Active Hepatitis B | 23-Jan-17 | Hepatitis Serology | HBsAg+; HBeAg- HCVAb-; | 23-Jan-17 | Co-Infections | None | |||||||
| DLS16-72192 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 4.00 | $95.00 | 43 Y | M | White | <-70C | 17-Oct-16 | Roche COBAS AmpliPrep | 1,140 IU/mL | 6-Oct-16 | Siemens TruGene HBV | Genotype D | 6-Oct-16 | Roche COBAS AmpliPrep | Positive | 13-Mar-2018 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | None | Additional Testing | ALT: 56 IU/L; AST: 32 IU/L; Bilirubin: 0.8 mg/dL; Serum Creatinine: 0.8 mg/dL; Chronic Hepatitis B | 6-Oct-2016 | Hepatitis Serology | HBsAg+ HBcAb+ HBeAb+ HCVAb- 6-Oct-2016 (CMIA) | Co-Infections | None | |||||
| DLS16-72193 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 11.00 | $95.00 | 37 Y | M | White | <-70C | 14-Nov-16 | Roche COBAS AmpliPrep | 20 IU/mL | 14-Nov-16 | Siemens TruGene HBV | Genotype D | 16-Nov-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | None | Additional Testing | ALT: 27 IU/L; AST: 14 IU/L; LDH: 145 IU/L; Bilirubin: 0.3 mg/dL; Serum Creatinine: 0.6 mg/dL; Chronic Active Hepatitis B | 14-Nov-2016 | Hepatitis Serology | HBsAg+ HBcAb+ HBeAb+ HCVAb- 14-Nov-2016 (CMIA) | Co-Infections | None | ||||||||
| DLS17-038201 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 1.00 | 5.00 | $40.00 | U/A | U/A | <-70C | 03-May-12 | Roche cobas | 88,167,700 IU/mL | Gene S Sequencing In-house Assay | D8 | Enzyme immunoassay | ayw2 | Serotype | $40.00 | HBsAg Titer | 192,000 ng/mL | Prism | 318.700 | 347.590 | 320.320 | Elisa | 30.500 | Confirmation | Pos | DGV Ultrio | Pos | Hepatitis Serology | HBc Positive, HBeAg Positive | |||||||||||
| DLS17-038202 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 1.00 | 5.00 | $40.00 | U/A | U/A | <-70C | Roche cobas | 1,543,655 IU/mL | Gene S Sequencing In-house Assay | D | Enzyme immunoassay | ayw2 | Serotype | $40.00 | HBsAg Titer | 96,000 ng/mL | Prism | 552.060 | 515.640 | 522.470 | Elisa | 50.847 | Confirmation | Pos | Hepatitis Serology | HBe Positive | ||||||||||||||
| DLS17-038203 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 1.00 | 7.00 | $40.00 | U/A | U/A | <-70C | 22-Sep-10 | Roche cobas | 2,811,723 IU/mL | Gene S Sequencing In-house Assay | D2 | Enzyme immunoassay | ayw2 | Serotype | $40.00 | HBsAg Titer | 96,000 ng/mL | Prism | 641.140 | 543.020 | 530.410 | Axsym | 120.630 | Confirmation | Pos | Hepatitis Serology | Hbc Positive, HBsAg Positive, HBe Positive | |||||||||||||
| DLS17-038209 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 1.00 | 5.00 | $40.00 | U/A | U/A | <-70C | 08-Sep-11 | Roche cobas | 13,961,137 IU/mL | Gene S Sequencing In-house Assay | D1 | Enzyme immunoassay | ayw2 | Serotype | $40.00 | HBsAg Titer | 96,000 ng/mL | Elisa | 50.847 | 49.180 | 50.847 | Prism | 494.030 | DGV | Pos | Mutation | P120T | Hepatitis Serology | HBc Positive, HBe Positive | |||||||||||
| DLS17-038215 | Hepatitis B (HBV) Genotype D | France | Citrated Plasma | 1.00 | 8.00 | $40.00 | U/A | U/A | <-70C | 24-Aug-12 | Roche cobas | 8,589,305 IU/mL | Gene S Sequencing In-house Assay | D2 | Enzyme immunoassay | ayw3 | Serotype | $40.00 | HBsAg Titer | 192,000 ng/mL | Prism | 385.800 | 444.870 | 423.080 | Elisa | 39.571 | DGV Ultrio | Pos | Hepatitis Serology | HBc Positive | |||||||||||||
| DLS0025522 | Hepatitis B (HBV) Genotype D | Italy | Serum | 1.00 | 11.00 | $95.00 | 51 | M | White | <-70C | 10-Jan-18 | Roche Cobas Ampliprep | 1,100,000 IU/mL | Siemens TruGene HBV | Genotype D | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Italy | Symptoms | None | Additional Testing | ALT: 56 IU/L | Creatinine: 1.5 mg/dL | Chronic Hepatitis B | 20-Dec-17 | Serology Results | HBsAg+ | HBcAb- | 20-Dec-17 |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.